The CD40 pathway in allograft rejection, acceptance, and tolerance

Current Opinion in Immunology

Volumn 9, Issue 5, 1997, Pages 641-647

  Larsen, Christian P ^a   Pearson, Thomas C ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 39; HLA B7 ANTIGEN; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; CELL FUNCTION; ENDOTHELIUM CELL; GRAFT PATENCY; GRAFT REJECTION; HELPER CELL; HUMAN; HYPERIMMUNOGLOBULINEMIA; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE CLONE; LYMPHOCYTE FUNCTION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; RAT; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION;

EID: 0030659503     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80043-X     Document Type: Article

References (67)

1. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, Goodwin RG. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 248:1990;1019-1023.
2. Hasbold J, Johnson LC, Atkins CJ, Clark EA, Klaus GG. Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies. Eur J Immunol. 24:1994;1835-1842.
3. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 180:1994;1263-1272.
4. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, Kiener PA, Aruffo A. Expression of functional CD40 by vascular endothelial cells. J Exp Med. 182:1995;33-40.
5. Yellin MJ, Brett J, Baum D, Matsushima A, Szabolcs M, Stern D, Chess L. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. of special interest J Exp Med. 182:1996;1857-1864 This paper, along with [4,6], represents the initial description of the function and expression of CD40 by endothelial cells. It suggests that CD40 - CD40 ligand interactions may regulate leukocyte traffic by modulating endothelial cell adhesion molecule expression.
6. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 92:1995;4342-4346.
7. Fries KM, Sempowski GD, Gaspari AA, Blieden T, Looney RJ, Phipps RP. CD40 expression by human fibroblasts. Clin Immunol Immunopathol. 77:1995;42-51.
8. Galy AH, Spits H. CD40 is functionally expressed on human thymic epithelial cells. J Immunol. 149:1992;775-782.
9. Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, Bonnefoy JY, Cosyns M, Weinberg A. Cholangiopáthy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IGM. J Immunol. 158:1997;977-983.
10. Denfeld RW, Hollenbaugh D, Fehrenbach A, Weiss JM, von Leoprechting A, Mai B, Voith U, Schopf E, Aruffo A, Simon JC. CD40 is functionally expressed on human keratinocytes. Eur J Immunol. 26:1996;2329-2334.
11. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 76:1994;959-962.
12. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, MacDuff BM, Anderson DM, Gimpel SD, Davis ST, Maliszewski CR, et al. Molecular and biological characterization of a murine ligand for CD40. Nature. 357:1992;80-82.
13. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch AS, Noelle RJ, Stamenkovic I, Ledbetter JA, Aruffo A. The human T cell antigen CD40L, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of CD40L with B cell co-stimulatory activity. EMBO J. 11:1992;4313-4321.
14. Peitsch MC, Jongeneel CV. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol. 5:1993;233-288.
15. Pietravalle F, Lecoanet-Henchoz S, Blasey H, Aubry JP, Elson G, Edgerton MD, Bonnefoy JY, Gauchat JF. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem. 271:1996;5965-5967.
16. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 182:1995;1777-1783.
17. ++ T cells. J Immunol. 151:1993;2497-2510.
18. Pinchuk LM, Klaus SJ, Magaletti DM, Pinchuk GV, Norsen JP, Clark EA. Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. J Immunol. 157:1996;4363-4670.
19. Hess S, Rensing EA, Schwabe R, Bufler P, Engelmann H. CD40 function in nonhematopoletic cells. Nuclear factor kappa B mobilization and induction of IL-6 production. J Immunol. 155:1995;4588-4595.
20. Sarma V, Lin Z, Clark L, Rust BM, Tewari M, Noelle RJ, Dixit VM. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem. 270:1995;12343-12346.
21. Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 269:1995;1424-1427.
22. Schauer SL, Wang Z, Sonenshein GE, Rothstein TL. Maintenance of nuclear factor-kappa B/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of I kappa B proteins. J Immunol. 157:1996;81-86.
23. L, cdk4 and cdk6: implication of their cooperation in selective B cell growth. J Immunol. 155:1995;5527-5535.
24. Wang Z, Karras JG, Howard RG, Rothstein TL. Induction of bcl-x by CD40 engagement rescues sig-induced apoptosis in murine B cells. J Immunol. 155:1995;3722-3725.
25. Merino R, Grillot DA, Simonian PL, Muthukkumar S, Fanslow WC, Bondada S, Nunez G. Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells. Dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. J Immunol. 155:1995;3830-3838.
26. Van Essen D, Kikutani H, Gray D. CD40 ligand-transduced costimulation of T cells in the development of helper function. Nature. 378:1995;620-623.
27. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M, et al. The CD40 ligand, CD40L, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 72:1993;291-300.
28. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 259:1993;990-993.
29. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature. 361:1993;541-543.
30. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 361:1993;539-541.
31. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. In vivo CD40-CD40L interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, CD40L. J Exp Med. 178:1993;1567-1575.
32. Renshaw BR, Fanslow WC III, Armitage RJ, Campbell KA, Liggitt D, Wright B, Davison BL, Maliszewski CR. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med. 180:1994;1889-1900.
33. Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity. 1:1994;167-178.
34. Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Flavell RA. Mice deficient for the CD40 ligand. Immunity. 1:1994;423-431.
35. Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, Bonnefoy JY, Cosyns M, Weinberg A. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IGM. J Immunol. 158:1997;977-983.
36. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature. 378:1995;617-620.
37. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 177:1993;925-935.
38. Pinchuk LM, Polacino PS, Agy MB, Klaus SJ, Clark EA. The role of CD40 and CD80 accessory cell molecules in dendritic cell-dependent HIV-1 infection. Immunity. 1:1994;317-325.
39. Cella M, Scheidegger D, Palmer LK, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 184:1996;747-752.
40. Guo Y, Wu Y, Shinde S, Sy MS, Aruffo A, Liu Y. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J Exp Med. 184:1996;955-961.
41. Kato T, Hakamada R, Yamane H, Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J Immunol. 156:1996;3932-3938.
42. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N, Schuler G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med. 184:1996;741-746.
43. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janeway CA Jr, aiFlavell RA. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. of special interest Science. 273:1996;1864-1867 This paper suggests that one of CD40L's major functions in the development of T cell responses is to upregulate B7 expression on APCs during the genesis of immune response.
44. Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A, Hendrix R, Pearson TC. CD40-CD40L interactions play a critical role during allograft rejection. of special interest Transplantation. 61:1996;4-9 This report indicates that the blockade of CD40L can profoundly impair graft rejection responses. The demonstration that early intragraft expression of B7 and T cell cytokine transcripts occurs in the present of such a blockade suggests that this blockade interrupts processes downstream of the initial T cell activation events.
45. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. of special interest Nature. 381:1996;434-438 The inhibition of skin graft rejection by single and combined CD40 and CD28 blockades, as reported in this paper, suggests that, although interrelated, CD40 and CD28 have distinct functions in the development of rejection.
46. Larsen CP, Ritchie SC, Hendrix R, Linsley PS, Hathcock KS, Hodes RJ, Lowry RP, Pearson TC. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol. 152:1994;5208-5219.
47. Rothstein TL, Wang JK, Panka DJ, Foote LC, Wang Z, Stanger B, Cui H, Ju ST, Marshak RA. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature. 374:1995;163-165.
48. Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. J Immunol. 155:1995;3329-3337.
49. Kiener PA, Moran DP, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble CD40L induces proinflammatory responses in human monocytes. J Immunol. 155:1995;4917-4925.
50. Peguet-Navarro J, Dalbiez-Gauthier C, Rattis FM, Van Kooten C, Banchereau J, Schmitt D. Functional expression of CD40 antigen on human epidermal Langerhans cells. J Immunol. 155:1995;4241-4247.
51. + T cells enhances IL-4 synthesis, provides the most direct evidence that CD40L may serve as a receptor which transduces a costimulatory signal to the T cell.
52. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today. 17:1996;487-492.
53. Tian L, Noelle R, Lawrence D. Activated T cells enhance nitric oxide production by murine splenic macrophages through CD40L and LFA-1. Eur J Immunol. 25:1995;306-309.
54. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol. 156:1996;3952-3960.
55. Bishop DK, Jutila MA, Sedmak DD, Beattie MS, Orosz CG. Lymphocyte entry into inflammatory tissues in vivo. Qualitative differences of high endothelial venule-like vessels in sponge matrix allografts vs isografts. J Immunol. 142:1989;4219-4224.
56. Pelletier RP, Morgan CJ, Sedmak DD, Miyake K, Kincade PW, Ferguson RM, Orosz CG. Analysis of inflammatory endothelial changes, including VCAM-1 expression, in murine cardiac grafts. Transplantation. 55:1993;315-320.
57. Sibley RK. Morphologic features of chronic rejection in kidney and less commonly transplanted organs. Clin Transplant. 8:1994;293-298.
58. Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, Durie FH, Noelle RJ, Mordes JP, Rossini AA. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA. 92:1995;9560-9564.
59. Durie FH, Aruffo A, Ledbetter J, Crassi KM, Green WR, Fast LD, Noelle RJ. Antibody to the ligand of CD40, CD40L, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest. 94:1994;1333-1338.
60. ++ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 158:1997;29-39.
61. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ. Costimulation blockade prevents rejection following primate renal allotransplanation. of special interest Proc Natl Acad Sci USA. 94:1997;8780-8794 This study is the first to show that blockade of the CD40L - CD40 pathway can markedly prolong allograft survival in a pre-clinical large animal model, the rhesus monkey.
62. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. of special interest Science. 273:1996;1862-1864 This report examines the interaction of the CD40L - CD40 and B7 - CD28 pathways in the cellular and humoral immune responses to hepatocytes transduced by adenoviral vectors in a murine model. The data indicate that the CD40L dependent activation of T cells occurs through signaling of CD40 on the APC which enhances the B7 co-stimulatory pathway.
63. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. of special interest Proc Natl Acad Sci USA. 93:1996;13967-13972 These authors demonstrate that the combination of anti-CD40L mAb with an infusion of donor antigens in the form of splenocytes induces long-term survival of mouse cardiac allografts. Analysis of this model indicates that the CD40 pathway can directly co-stimulate T cells, independently of its effect on the B7 - CD28 pathway.
64. Larsen CP, Ritchie SC, Hendrix R, Linsley PS, Hathcock KS, Hodes RJ, Lowry RP, Pearson TC. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol. 152:1994;5208-5219.
65. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science. 258:1992;1156-1159.
66. Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, Xu JC, Shultz LD, Roopesian D, Flavell RA, et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity. 2:1995;645-653.
67. Niimi M, Rawsthorne MA, Morris PJ, Wood KJ. B7-2+ low density APCs are as effective as B7-2- small resting B cells in inducing specific unresponsiveness to minor histocompatibility (miH) antigen(s) in vivo. Ricciardi-Castagnoli P. Dendritic Cells in Fundamental and Clinical Immunology. 1997;265-269 Plenum Publishing Corporation, New York.